Concepedia

Author

Dominik Hlauschek

Medical University of ViennaORCID

Also Known As

D Hlauschek, D. Hlauschek, Dominik Hlauschek, Hlauschek, Dominik

85

Publications

446

Citations

8

H-Index

11

Concepts

All Affiliations

Medical University of ViennaAustrian Breast & Colorectal Cancer Study GroupComprehensive Cancer Center ViennaHirslanden Klinik St. AnnaMedical University of Graz
DH

About

Dominik Hlauschek is an author at Medical University of Vienna specializing in radiation oncology, breast cancer, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

118

2

Obstetrics

2

2

118

3

Health Sciences

1

1

23

4

Clinical Trials

1

1

23

5

Menopause

1

1

95

Dominik Hlauschek

×

7

Publications

375

Citations

7

H-Index

YearCitations

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Cristina Saura, Dominik Hlauschek, Mafalda Oliveira,

The Lancet Oncology

2019

95

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone

Ivana Šestak, Miguel Martín, Peter Dubsky,

Breast Cancer Research and Treatment

2019

86

Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2− Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only

Martin Filipits, Peter Dubsky, Margaretha Rudas,

Clinical Cancer Research

2019

73

Randomized clinical trial of the effect of a fibrin sealant patch on pancreatic fistula formation after pancreatoduodenectomy

Martin Schindl, R. Függer, P. Götzinger,

British journal of surgery

2018

42

Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial

Georg Pfeiler, Dominik Hlauschek, Erica L. Mayer,

Journal of Clinical Oncology

2023

33

Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)

Cristina Saura, Evandro de Azambuja, Dominik Hlauschek,

Annals of Oncology

2017

23

ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6

Martin Filipits, Margaretha Rudas, Christian F. Singer,

ESMO Open

2021

23

Page 1